Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 9, 2007, Pages 684-698

  Loria, P ^a   Lonardo, A ^a   Bellentani, S ^b,c   Day, C P ^d   Marchesini, G ^e   Carulli, N ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Ospedale di Carpi   (Italy)

^c Liver Research Center   (Italy)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atherosclerosis; Cardiovascular risk; Fatty liver; Non alcoholic steatohepatitis

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMORBIDITY; DISEASE PREDISPOSITION; FATTY LIVER; GENETIC PREDISPOSITION; HUMAN; METABOLIC SYNDROME X; PATHOLOGY; PREVALENCE; REVIEW; RISK FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMORBIDITY; DISEASE SUSCEPTIBILITY; FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METABOLIC SYNDROME X; PREVALENCE; RISK FACTORS;

EID: 35348845091     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2007.01.007     Document Type: Review

References (132)

1. Farrell G.C. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. J Gastroenterol Hepatol 18 (2003) 124-138 10.1046/j.1440-1746.2003.02989.x
2. Loria P., Lonardo A., and Carulli N. Should nonalcoholic fatty liver disease be renamed?. Dig Dis 23 (2005) 72-82 10.1159/000084728
3. Loria P., Lonardo A., and Carulli N. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 (2004) 1748 10.1002/hep.20252
4. Lonardo A., Carani C., Carulli N., and Loria P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 44 (2006) 1196-1207 10.1016/j.jhep.2006.03.005
5. Bugianesi E., McCullough A.J., and Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005) 987-1000 10.1002/hep.20920
6. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752 10.1161/circulationaha.105.169404
7. Adams L.A., Feldstein A., Lindor K.D., and Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39 (2004) 909-914 10.1002/hep.20140
8. Liangpunsakul S., and Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?. J Clin Gastroenterol 37 (2003) 340-343
9. Targher G., Bertolini L., Rodella S., Zoppini G., Scala L., Zenari L., et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 64 (2006) 679-683 10.1111/j.1365-2265.2006.02527.x
10. Bujalska I.J., Kumar S., and Stewart P.M. Does central obesity reflect "Cushing's disease of the omentum"?. Lancet 349 (1997) 1210-1213 10.1016/S0140-6736(96)11222-8
11. Makhsida N., Shah J., Yan G., Fisch H., and Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 174 (2005) 827-834 [MANCA]
12. Diehl A.M. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 619-638 10.1016/j.cld.2004.04.012
13. Younossi Z.M., Baranova A., Ziegler K., Del G.L., Schlauch K., Born T.L., et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42 (2005) 665-674 10.1002/hep.20838
14. Musso G., Gambino R., Durazzo M., Biroli G., Carello M., Faga E., et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42 (2005) 1175-1183 10.1002/hep.20896
15. Musso G., Gambino R., Biroli G., Carello M., Faga E., Pacini G., et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 100 (2005) 2438-2446 10.1111/j.1572-0241.2005.00297.x
16. Aygun C., Senturk O., Hulagu S., Uraz S., Celebi A., Konduk T., et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 18 (2006) 175-180
17. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24 (2004) 29-33 10.1161/01.ATV.0000099786.99623.EF
18. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89 10.1161/01.ATV.0000048856.22331.50
19. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
20. Pagano C., Soardo G., Pilon C., Milocco C., Basan L., Milan G., et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 91 (2006) 1081-1086 10.1210/jc.2005-1056
21. Pittas A.G., Joseph N.A., and Greenberg A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89 (2004) 447-452
22. Lonardo A., Lombardini S., Ricchi M., Scaglioni F., and Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 22 Suppl. 2 (2005) 64-70
23. Tsushima Y., Aoki J., and Endo K. The effect of fatty infiltration on the liver tissue enhancement during portal phase computed tomography. Acad Radiol 10 (2003) 1008-1012
24. Magalotti D., Marchesini G., Ramilli S., Berzigotti A., Bianchi G., and Zoli M. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig Liver Dis 36 (2004) 406-411
25. McCuskey R.S., Ito Y., Robertson G.R., McCuskey M.K., Perry M., and Farrell G.C. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 40 (2004) 386-393 10.1002/hep.20302
26. Tanne F., Gagnadoux F., Chazouilleres O., Fleury B., Wendum D., Lasnier E., et al. Chronic liver injury during obstructive sleep apnea. Hepatology 41 (2005) 1290-1296 10.1002/hep.20725
27. Li J., Thorne L.N., Punjabi N.M., Sun C.K., Schwartz A.R., Smith P.L., et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 97 (2005) 698-706 10.1161/01.res.0000183879.60089.a9
28. Li J., Grigoryev D.N., Ye S.Q., Thorne L., Schwartz A.R., Smith P.L., et al. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol 99 (2005) 1643-1648 10.1152/japplphysiol.00522.2005
29. Wanless I.R., and Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 24 (2004) 99-106 10.1055/s-2004-823104
30. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241 10.1038/35025203
31. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30 (2004) 498-505
32. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 (2004) 1222-1225 10.1002/hep.20420
33. Marchesini G., Marzocchi R., Agostini F., and Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16 (2005) 421-427
34. Hsueh W.A., Lyon C.J., and Quinones M.J. Insulin resistance and the endothelium. Am J Med 117 (2004) 109-117 10.1016/j.amjmed.2004.02.042
35. Steinberg H.O., Tarshoby M., Monestel R., Hook G., Cronin J., Johnson A., et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100 (1997) 1230-1239
36. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192 10.1053/gast.2001.23256
37. Caldwell S.H., Chang C.Y., Nakamoto R.K., and Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 595-617 10.1016/j.cld.2004.04.009
38. Cortez-Pinto H., Chatham J., Chacko V.P., Arnold C., Rashid A., and Diehl A.M. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282 (1999) 1659-1664
39. Nakamuta M., Kohjima M., Morizono S., Kotoh K., Yoshimoto T., Miyagi I., et al. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 16 (2005) 631-635
40. Baffy G. Uncoupling protein-2 and non-alcoholic fatty liver disease. Front Biosci 10 (2005) 2082-2096
41. Liou I., and Kowdley K.V. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 40 (2006) S11-S16
42. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152 10.1172/JCI200422422
43. Fajas L., Schoonjans K., Gelman L., Kim J.B., Najib J., Martin G., et al. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol 19 (1999) 5495-5503 [PMID: 10409739]
44. Bertrand L., Ginion A., Beauloye C., Hebert A.D., Guigas B., Hue L., et al. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol 291 (2006) H239-H250 10.1152/ajpheart.01269.2005
45. Steffensen K.R., and Gustafsson J.A. Putative metabolic effects of the liver X receptor (LXR). Diabetes 53 Suppl. 1 (2004) S36-S42
46. Madamanchi N.R., Vendrov A., and Runge M.S. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25 (2005) 29-38 10.1161/01.atv.0000150649.39934.13
47. Verma S., and Szmitko P.E. The vascular biology of peroxisome proliferator-activated receptors: Modulation of atherosclerosis. Can J Cardiol 22 Suppl. B (2006) 12B-17B
48. Zelcer N., and Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116 (2006) 607-614 10.1172/JCI27883
49. Lee W.J., Lee I.K., Kim H.S., Kim Y.M., Koh E.H., Won J.C., et al. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase. Arterioscler Thromb Vasc Biol. 25 (2005) 2488-2494 10.1161/01.atv.0000190667.33224.4c
50. Neuschwander-Tetri B.A., and Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37 (2003) 1202-1219 10.1053/jhep.2003.50193
51. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 (2000) 112-117
52. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., and Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42 (2005) 44-52 10.1002/hep.20734
53. Hilden M., Christoffersen P., Juhl E., and Dalgaard J.B. Liver histology in a 'normal' population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 12 (1977) 593-597
54. Ground K.E. Liver pathology in aircrew. Aviat Space Environ Med 53 (1982) 14-18
55. Wanless I.R., and Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 (1990) 1106-1110
56. McCullough A.J. The epidemiology and risk factors of NASH. In: Farell G.C., George J., De la M.H., and McCollough A.J. (Eds). Fatty liver disease: NASH and related disorders (2005), Blackwell Publishing, Malden, MA 23-37
57. Marcos A., Fisher R.A., Ham J.M., Olzinski A.T., Shiffman M.L., Sanyal A.J., et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 69 (2000) 2410-2415
58. Hwang S., Lee S.G., Jang S.J., Cho S.H., Kim K.H., Ahn C.S., et al. The effect of donor weight reduction on hepatic steatosis for living donor liver transplantation. Liver Transpl 10 (2004) 721-725 10.1002/lt.20172
59. Dixon J.B., Bhathal P.S., and O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 (2001) 91-100 10.1053/gast.2001.25540
60. Marceau P., Biron S., Hould F.S., Marceau S., Simard S., Thung S.N., et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84 (1999) 1513-1517
61. Del Gaudio A., Boschi L., Del Gaudio G.A., Mastrangelo L., and Munari D. Liver damage in obese patients. Obes Surg 12 (2002) 802-804 10.1381/096089202320995592
62. Luyckx F.H., Desaive C., Thiry A., Dewe W., Scheen A.J., Gielen J.E., et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22 (1998) 222-226
63. Silverman E.M., Sapala J.A., and Appelman H.D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 104 (1995) 23-31
64. Kral J.G., Thung S.N., Biron S., Hould F.S., Lebel S., Marceau S., et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135 (2004) 48-58 10.1016/j.surg.2003.10.003
65. Bellentani S., Bedogni G., Miglioli L., and Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 16 (2004) 1087-1093
66. Nomura H., Kashiwagi S., Hayashi J., Kajiyama W., Tani S., and Goto M. Prevalence of fatty liver in a general population of Okinawa. Japan. Jpn J Med 27 (1988) 142-149
67. Lonardo A., Bellini M., Tartoni P., and Tondelli E. The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 29 (1997) 351-356
68. Omagari K., Kadokawa Y., Masuda J., Egawa I., Sawa T., Hazama H., et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 17 (2002) 1098-1105 10.1046/j.1440-1746.2002.02846.x
69. Araujo L.M., De Oliveira D.A., and Nunes D.S. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diabetes Metab 24 (1998) 458-462
70. el-Hassan A.Y., Ibrahim E.M., al-Mulhim F.A., Nabhan A.A., and Chammas M.Y. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 65 (1992) 774-778
71. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395 10.1002/hep.20466
72. Patt C.H., Yoo H.Y., Dibadj K., Flynn J., and Thuluvath P.J. Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. Dig Dis Sci 48 (2003) 797-801 10.1023/A:1022809430756
73. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967 10.1111/j.1572-0241.2003.07486.x
74. Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35 (2002) 367-372 10.1053/jhep.2002.30690
75. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923 10.1053/jhep.2003.50161
76. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
77. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143 (2005) 722-728
78. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 745-750 10.1053/gast.2002.35354
79. Donati G., Stagni B., Piscaglia F., Venturoli N., Morselli-Labate A.M., Rasciti L., et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 53 (2004) 1020-1023
80. Angulo P., Keach J.C., Batts K.P., and Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999) 1356-1362 10.1002/hep.510300604
81. Harrison S.A., Torgerson S., and Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98 (2003) 2042-2047 10.1111/j.1572-0241.2003.07659.x
82. Ratziu V., Bonyhay L., Di Martino.V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 (2002) 1485-1493 10.1053/jhep.2002.33324
83. Targher G., Bertolini L., Padovani R., Zenari L., Zoppini G., and Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27 (2004) 2498-2500
84. Brea A., Mosquera D., Martin E., Arizti A., Cordero J.L., and Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25 (2005) 1045-1050 10.1161/01.atv.0000160613.57985.18
85. Villanova N., Moscatiello S., Ramilli S., Bugianesi E., Magalotti D., Vanni E., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 (2005) 473-480 10.1002/hep.20781
86. Bellentani S., Tiribelli C., Saccoccio G., Sodde M., Fratti N., De M.C., et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 20 (1994) 1442-1449 [MANCA]
87. Targher G. Non-alcoholic fatty liver disease as a determinant of cardiovascular disease. Atherosclerosis 190 (2007) 18-19
88. Musso G., Gambino R., De M.F., Cassader M., Rizzetto M., Durazzo M., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37 (2003) 909-916 10.1053/jhep.2003.50132
89. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., McCarthy P.J., Grose R.H., and Cummins A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48 (2001) 206-211
90. Struben V.M., Hespenheide E.E., and Caldwell S.H. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 108 (2000) 9-13 10.1016/S0002-9343(99)00315-0
91. Willner I.R., Waters B., Patil S.R., Reuben A., Morelli J., and Riely C.A. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 96 (2001) 2957-2961 10.1111/j.1572-0241.2001.04667.x
92. Browning J.D., Kumar K.S., Saboorian M.H., and Thiele D.L. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 99 (2004) 292-298 10.1111/j.1572-0241.2004.04059.x
93. Caldwell S.H., Harris D.M., Patrie J.T., and Hespenheide E.E. Is NASH underdiagnosed among African Americans?. Am J Gastroenterol 97 (2002) 1496-1500 10.1111/j.1572-0241.2002.05795.x
94. Bernard S., Touzet S., Personne I., Lapras V., Bondon P.J., Berthezene F., et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 43 (2000) 995-999
95. Namikawa C., Shu-Ping Z., Vyselaar J.R., Nozaki Y., Nemoto Y., Ono M., et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 40 (2004) 781-786 10.1016/j.jhep.2004.01.028
96. Song J., da Costa K.A., Fischer L.M., Kohlmeier M., Kwock L., Wang S., et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J 19 (2005) 1266-1271
97. George D.K., Goldwurm S., MacDonald G.A., Cowley L.L., Walker N.I., Ward P.J., et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114 (1998) 311-318
98. Bugianesi E., Manzini P., D'Antico S., Vanni E., Longo F., Leone N., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 (2004) 179-187 10.1002/hep.20023
99. Saksena S., Leathart J.B., Daly A.K., and Day C.P. Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 38 (2003) 22A-23A
100. Baldini M., Lohman I.C., Halonen M., Erickson R.P., Holt P.G., and Martinez F.D. A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 20 (1999) 976-983
101. Jarvelainen H.A., Orpana A., Perola M., Savolainen V.T., Karhunen P.J., and Lindros K.O. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 33 (2001) 1148-1153 10.1053/jhep.2001.24236
102. Day C. CD14 promoter polymorphism associated with risk of NASH. J Hepatol 36 (2002) 21A
103. Valenti L., Fracanzani A.L., Dongiovanni P., Santorelli G., Branchi A., Taioli E., et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 274-280 10.1053/gast.2002.31065
104. Grove J., Daly A.K., Bassendine M.F., and Day C.P. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 26 (1997) 143-146 10.1002/hep.510260119
105. Dixon J.B., Bhathal P.S., Jonsson J.R., Dixon A.F., Powell E.E., and O'Brien P.E. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 39 (2003) 967-971 10.1016/S0168-8278(03)00459-8
106. Teli M.R., James O.F., Burt A.D., Bennett M.K., and Day C.P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22 (1995) 1714-1719
107. Dam-Larsen S., Franzmann M., Andersen I.B., Christoffersen P., Jensen L.B., Sorensen T.I., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53 (2004) 750-755
108. Adams L.A., Sanderson S., Lindor K.D., and Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 (2005) 132-138 10.1016/j.jhep.2004.09.012
109. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., and McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
110. Bellentani S., Bedogni G., Miglioli L., Masutti F., Croce L.S., Castiglione A., et al. Natural history and incidence of non alcoholic and alcoholic fatty liver disease (NAFLD, AFLD) in general population with alteration of liver enzymes. J Hepatol 42 2 (2005) 42A-43A
111. Fassio E., Alvarez E., Dominguez N., Landeira G., and Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826 10.1002/hep.20410
112. Hui J.M., Kench J.G., Chitturi S., Sud A., Farrell G.C., Byth K., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38 (2003) 420-427 10.1053/jhep.2003.50320
113. Adams L.A., Lymp J.F., St S.J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121 10.1053/j.gastro.2005.04.014
114. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002) 134-140 10.1053/gast.2002.34168
115. Gramlich T., Kleiner D.E., McCullough A.J., Matteoni C.A., Boparai N., and Younossi Z.M. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 35 (2004) 196-199 10.1016/j.humpath.2003.09.018
116. Jepsen P., Vilstrup H., Mellemkjaer L., Thulstrup A.M., Olsen J.H., Baron J.A., et al. Prognosis of patients with a diagnosis of fatty liver - a registry-based cohort study. Hepatogastroenterology 50 (2003) 2101-2104
117. Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., and Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164 (2004) 1066-1076
118. De Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., and Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22 (1999) 756-761
119. Verlato G., Zoppini G., Bonora E., and Muggeo M. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26 (2003) 1047-1051
120. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003) 1625-1638
121. Marchesini G., Forlani G., Cerrelli F., Manini R., Natale S., Baraldi L., et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med 21 (2004) 383-387 10.1111/j.1464-5491.2004.01115.x
122. Marchesini G., Melchionda N., Apolone G., Cuzzolaro M., Mannucci E., Corica F., et al. The metabolic syndrome in treatment-seeking obese persons. Metabolism 53 (2004) 435-440 10.1016/j.metabol.2003.10.026
123. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
124. Ninomiya J.K., L'Italien G., Criqui M.H., Whyte J.L., Gamst A., and Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109 (2004) 42-46 10.1161/01.cir.0000108926.04022.0C
125. McNeill A.M., Rosamond W.D., Girman C.J., Golden S.H., Schmidt M.I., East H.E., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28 (2005) 385-390
126. Lautamaki R., Borra R., Iozzo P., Komu M., Lehtimaki T., Salmi M., et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 291 (2006) E282-E290 10.1152/ajpendo.00604.2005
127. Mullen M.J., Kharbanda R.K., Cross J., Donald A.E., Taylor M., Vallance P., et al. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res 88 (2001) 145-151
128. Anderson K.M., Wilson P.W., Odell P.M., and Kannel W.B. An updated coronary risk profile. A statement for health professionals. Circulation 83 (1991) 356-362
129. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105 (2002) 310-315
130. Bugianesi E., Marzocchi R., Villanova N., and Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol 18 (2004) 1105-1116 10.1016/j.bpg.2004.06.025
131. Tilg H., and Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 148-155 10.1038/ncpgasthep0116
132. Zoppini G., Targher G., Venturi C., Zamboni C., and Muggeo M. Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. Clin Endocrinol (Oxf) 61 (2004) 711-715